Brief: Adverum Biotechnologies Announces Positive Aflibercept Protein Level Data From The Luna Phase 2 Trial
26/09/2023 23:22
Sept 26 (Reuters) - Adverum Biotechnologies Inc
ADVM.O :
* ADVERUM BIOTECHNOLOGIES ANNOUNCES POSITIVE AFLIBERCEPT
PROTEIN
LEVEL DATA FROM THE LUNA PHASE 2 TRIAL
* ADVERUM BIOTECHNOLOGIES INC - IXO-VEC HAS BEEN WELL
TOLERATED
WITH A FAVORABLE PRELIMINARY SAFETY PROFILE
* ADVERUM BIOTECHNOLOGIES INC - INITIAL PHASE 2 LUNA
EFFICACY AND
SAFETY DATA ANTICIPATED IN Q4 2023
Source text for Eikon: ID:nGNX8bl9xJ
Further company coverage: ADVM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adverum Biotechnologies
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Adverum Reminds Stockholders To Tender Their Shares Into The Offer By Lilly
Brief: Adverum Biotechnologies Inc - Are-Nc Region No. 21 Llc Terminates Certain Lease Agreement With Adverum Biotechnologies - SEC Filing
Eli Lilly bets on eye care with buyout of gene therapy developer Adverum (updated)